Visiongain has published a new report on Anti-Infective Vaccines Market Report Report to 2031. According to the Visiongain analysis, the global Anti-Infective Vaccines market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Anti-Infective Vaccines market is segmented based on product type, by disease type and by end user. On basis of type, the market is categorized as (Live/attenuated Vaccines, Inactivated Vaccines, Conjugate vaccines, toxoid vaccine, Others) by Disease Type Bacterial diseases (Tuberculosis vaccine. Typhoid vaccine, Diphtheria and Tetanus vaccines, Others) Viral Diseases (Influenza vaccine, Hepatitis vaccine, Polio vaccine, Others) by End Users (Hospitals, Clinics, Others). The report includes detailed Profiles of Leading Anti-Infective Vaccines Companies. PLUS COVID-19 Recovery Scenarios.

Global Anti-Infective Vaccines Market was valued at US$XX billion in 2020 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The rising awareness for infectious diseases and the prevalence of infectious diseases are some of the factors driving the growth of the anti-infective vaccine market.

COVID-19 Impact on the Global Anti-Infective Vaccines Market
The COVID-19 pandemic has hugely affected the economic and healthcare system and increased various significant challenges. In response to the COVID-19, a lockdown was initiated as a safety measure, implemented with isolation, social distancing, and quarantine. This will likely reduce community transmission of many VPDs. However, it is a huge challenge for the healthcare sector to deliver immunizations on time. The reduced vaccine supply has significantly decreased immunization has boosted the anti-infective vaccine market.

Market Drivers

Priority review vouchers (PRVs), development of new vaccines for infectious diseases.
Priority review vouchers (PRVs) are low-cost innovative mechanisms that are motivated for the development of new medicines and vaccines for infectious diseases. The Food and Drug Administration (FDA) has issued PRVs, which allow its receiver to accelerate the review of any one of its new drug & vaccine products.

Rising prevalence of infectious diseases.
According to WHO, infectious diseases are the world's biggest killer, which accounts for more than 13 million deaths per year, one in two deaths in developing countries. However, the cost-effective vaccines for infectious diseases are not available. Almost 90% of deaths are caused due to a handful of infectious diseases such as pneumonia, tuberculosis, malaria, measles, and HIV. In developing countries, the infectious diseases are increasing rapidly, however, the advancements in vaccine development & cost-effective solutions have the potential to boost the anti-infective vaccine market.

Market Opportunities

Increasing old age population
The population is aging; almost every country is experiencing growth of older persons in their population. Influenza and pneumonia are among the sixth leading cause of death in America, about 90% of which occur in senior adults. The weakened immunity in the elderly, associated with other chronic conditions, increases the risk to develop severe influenza. The risk of infection increases among the elderly, as it can be easily transmitted by coughing and sneezing. However, pneumonia can be effectively prevented by the pneumococcal vaccine, and it is highly recommended for nursing home residents.

Competitive Landscape
Pfizer, Merck & Co., Sanofi Pasteur Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Biologicals, AstraZeneca , Organon Teknika Corp LLC, Emergent BioDefense Operations Lansing Inc., MedImmune LLC, and Novartis are some of the key players contributing to the growth of the global Anti-Infective Vaccines market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.

For instance, In March 2020, Pfizer has initiated efforts to advance antiviral therapies and develop a vaccine against Covid-19. The company is engaged with BioNTech to develop potential mRNA coronavirus vaccine. The development of new vaccine enables prevention of infectious disease.

In December 2019, The U.S. Food and Drug Administration announced the approval of Ervebo, it is first FDA-approved vaccine to prevent Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals 18 years of age and older. However, the risk associated with Ebola virus disease in the U.S. remains low, the U.S. government committed to fight devastating Ebola outbreaks in Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.